Your AI-Trained Oncology Knowledge Connection!
Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML
Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL
Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma
2 Commerce Drive
Cranbury, NJ 08512